| Scrip code | 533259 |
|---|---|
| NSE Symbol | HEALTHX |
| MSEI Symbol | NOTLISTED |
| ISIN | INE019J01013 |
| Name of company | HEALTH X PLATFORM LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 30-05-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 22-05-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Fourth quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Audited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Audited |
| Segment Reporting | Multi segment |
| Description of single segment | |
| Start date and time of board meeting | 30-05-2026 15:00:00 |
| End date and time of board meeting | 30-05-2026 16:30:00 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Indirect |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | |||
| (i) | Interest Income | 19.54 | 79.72 |
| (ii) | Dividend Income | 2.45 | 89.93 |
| (iii) | Rental Income | 0.00 | 0.00 |
| (iv) | Fees and commission Income | 0.00 | 0.00 |
| (v) | Net gain on fair value changes | (460.82) | 1,161.38 |
| (vi) | Net gain on derecognition of financial instruments under amortised cost category | 0.00 | 0.00 |
| (vii) | Sale of products (including Excise Duty) | 37,914.20 | 1,30,349.55 |
| (viii) | Sale of services | (99.97) | 243.40 |
| (ix) | Other revenue from operations | ||
| 1 | Other financial income | 2.61 | 2.61 |
| Total other revenue from operations | 2.61 | 2.61 | |
| Total Revenue From Operations | 37,378.01 | 1,31,926.59 | |
| Other income | 1,375.96 | 5,827.08 | |
| Total income | 38,753.97 | 1,37,753.67 | |
| 2 | Expenses | ||
| Cost of materials consumed | 9.97 | 79.74 | |
| Purchases of stock-in-trade | 37,355.58 | 1,24,888.13 | |
| Changes in inventories of finished goods, work-in-progress and stock-in-trade | (2,306.05) | (4,127.58) | |
| Employee benefit expense | 2,503.75 | 8,396.50 | |
| Finance costs | 48.82 | 78.17 | |
| Depreciation, depletion and amortisation expense | 194.08 | 660.29 | |
| Fees and commission expense | 0.00 | 0.00 | |
| Net loss on fair value changes | 0.00 | 0.00 | |
| Net loss on derecognition of financial instruments under amortised cost category | 0.00 | 0.00 | |
| Impairment on financial instruments | 0.00 | 0.00 | |
| (f) | Other expenses | ||
| 1 | Other Expenses | 2,334.30 | 7,901.48 |
| Total other expenses | 2,334.30 | 7,901.48 | |
| Total expenses | 40,140.45 | 1,37,876.73 | |
| 3 | Total profit before exceptional items and tax | (1,386.48) | (123.06) |
| 4 | Exceptional items | (96.09) | (112.70) |
| 5 | Total profit before tax | (1,482.57) | (235.76) |
| 7 | Tax expense | ||
| 8 | Current tax | 17.54 | 80.66 |
| 9 | Deferred tax | (203.23) | (171.69) |
| 10 | Total tax expenses | (185.69) | (91.03) |
| 11 | Net Profit Loss for the period from continuing operations | (1,296.88) | (144.73) |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 17 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 14 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 15 | Total profit (loss) for period | (1,296.88) | (144.73) |
| 16 | Other comprehensive income net of taxes | 147.04 | 218.41 |
| 17 | Total Comprehensive Income for the period | (1,149.84) | 73.68 |
| 18 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | (1,117.13) | 117.59 | |
| Total profit or loss, attributable to non-controlling interests | (179.75) | (262.32) | |
| 19 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | (999.95) | 285.43 | |
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | (149.89) | (211.75) | |
| 20 | Details of equity share capital | ||
| Paid-up equity share capital | 3,181.05 | 3,181.05 | |
| Face value of equity share capital | 10 | 10 | |
| 21 | Reserves excluding revaluation reserve | 60,907.76 | |
| 22 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings per share from continuing operations | -3.51 | 0.37 | |
| Diluted earnings per share from continuing operations | -3.51 | 0.37 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings per share from discontinued operations | 0 | 0 | |
| Diluted earnings per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings per share | -3.51 | 0.37 | |
| Diluted earnings per share | -3.51 | 0.37 | |
| 23 | Debt equity ratio | ||
| 24 | Debt service coverage ratio | ||
| 25 | Interest service coverage ratio | ||
| 26 | Disclosure of notes on financial results | Textual Information(1) | |
| 23 | Debt equity ratio | |
|---|---|---|
| 24 | Debt service coverage ratio | |
| 25 | Interest service coverage ratio |
| Textual Information(1) | 1. The above Audited Consolidated Financial Results for the quarter and year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on May 30, 2026. The Consolidated financial results for the year ended March 31, 2026 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LODR) Regulation, 2015. 2. The Company has identified the following segments : a) Financial Services - consists mainly of financing of loans and investment in shares and securities, financial consultancy, professional fees, wealth management, financial planning, distribution and related services. b) Healthcare Network - includes activities for pathology and trading & distribution of healthcare, FMCG and other pharmaceutical products through e-commerce platform and diagnostic services which consist of pathological / non pathological investigations c) Others - includes trading in other products (excluding financial & healthcare products). 3. Pursuant to the approval by the Ministry of Corporate Affairs, the Company changed its name from “Sastasundar Ventures Limited” to “Health X Platform Limited” during the year ended March 31, 2026. 4. During the year, Sastasundar Healthbuddy Limited (“SHBL”), a material subsidiary of the Company, completed a buy-back of 20,27,534 fully paid-up equity shares from Mitsubishi Corporation for an aggregate consideration of Rs. 10,000.00 lakhs. Pursuant to the completion of the said buy-back and extinguishment of the shares bought back, the Company’s shareholding in SHBL increased from 72.14% to 78.89%. 5. During the current year, the sale of Happymate Foods Limited, step- down subsidiary of the company, has been completed, and accordingly, the financial results of the said entity have been consolidated in the books of accounts up to May 30, 2025, being the date on which it ceases to be a subsidiary of Sastasundar Healthbuddy Limited. 6. During the previous year, the subsidiary of the company, Sastasundar Healthbuddy Limited, has liquidated its investment in Associate Company i.e. Flipkart Health Limited on October 29, 2024. Share of Profit/ (Loss) from an associate company has been consolidated till October 29, 2024. 7. Exceptional items represent the gain/ (loss) on following transaction/ event: a. During the previous year, the management of one of the step down subsidiary, Genu Path Labs Limited, has evaluated its business operation and Property, Plant & Equipment has been impaired. Accordingly the company has accounted for an impairment loss of Rs 72.37 Lakhs and disclosed the same as Exceptional items in the consolidated financial result for the year ended March 31, 2025. In the consolidated financial results for the nine months ended December 31, 2025, an impairment loss of Rs. 16.61 lakhs had already been recognised. Further, during the current quarter ended March 31, 2026, a reversal of impairment loss of Rs. 10.68 lakhs was recognised in the consolidated financial results. Consequently, a net impairment loss of Rs. 5.93 lakhs has been recognised as “Exceptional Items” in accordance with Ind AS 36 in the consolidated financial results for the year ended March 31, 2026. b. On November 21, 2025, the Government of India notified four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 consolidating 29 hitherto existing labour laws. The Ministry of Labour & Employment published draft Rules and FAQs to enable assessment of the financial impact due to these changes in regulations. The management of the subsidiary of the company, Sastasundar Healthbuddy Limited has assessed and disclosed the incremental impact of Rs. 106.77 Lakhs of these changes as an Exceptional items in the consolidated financial result for the year ended March 31, 2026. c. During the Financial Year 2022-23, subsidiaries of the Company had expensed Rs. 796.45 Lakhs under the heading “Exceptional Item”. During the previous year, Sastasundar Healthbuddy Limited, subsidiary of the Company has now recovered Rs. 128.00 Lakhs against the aforesaid amount which has been booked as income in the consolidated financial result for the year ended March 31, 2025 under the heading Exceptional items including Rs. 28.00 Lakhs of quarter March 31, 2025. d. During the previous year, the subsidiary of the company, Sastasundar Healthbuddy Limited, has liquidated its investment held in the form of 0.01% Non-Cumulative Compulsory Convertible Preference share and Equity shares in Flipkart Health Limited on October 29, 2024 as per Share Purchase Agreement dated October 28, 2024 and received a consideration of Rs. 9,717.29 Lakhs in aggregate. This has resultant loss of Rs 19,118.54 Lakhs has been booked as exceptional items in the consolidated financial result for the year ended March 31, 2025. 8. Genu Path Labs Limited, step- down subsidiary of the company, commenced its operations in the diagnostics and healthcare services segment in 2018 with a vision to establish itself as a trusted brand. Since inception, the company has undertaken several initiatives to develop its service network and physical presence. However, these efforts have not yielded the expected outcomes, resulting in operational losses Additionally, Sastasundar Healthbuddy Limited has assured its continued financial support to implement the revised strategies aimed at reviving and strengthening the business. 9. Pursuant to the Order dated February 12, 2026 passed by the Hon’ble NCLT, Kolkata Bench, approving the reduction of share capital of Genu Path Labs Limited, a step-down subsidiary under Sections 66 and 52 of the Companies Act, 2013, Genu Path Labs Limited has reduced the face value of its equity shares from Rs. 10/- each to Rs. 1/- each with effect from the appointed date of January 01, 2025. 10. The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures for the Year ended March 31, 2026 and unaudited figures for the nine month ended December 31, 2025. 11. Previous period's / year's figures have been re-grouped / re-classified wherever necessary. |
|---|
| Particulars | Year ended (dd-mm-yyyy) | |
|---|---|---|
| A | Date of start of reporting period | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited |
| D | Nature of report standalone or consolidated | Consolidated |
| Statement of cash flows | ||
| Cash flows from used in operating activities | ||
| Profit before tax | (235.76) | |
| Adjustments for reconcile profit (loss) | ||
| Adjustments for finance costs | 78.17 | |
| Adjustments for decrease (increase) in inventories | (3,435.07) | |
| Adjustments for decrease (increase) in trade receivables, current | 183.23 | |
| Adjustments for decrease (increase) in trade receivables, non-current | 0.00 | |
| Adjustments for decrease (increase) in other current assets | 0.00 | |
| Adjustments for decrease (increase) in other non-current assets | (1,676.33) | |
| Adjustments for other financial assets, non-current | 0.00 | |
| Adjustments for other financial assets, current | 386.61 | |
| Adjustments for other bank balances | 0.00 | |
| Adjustments for increase (decrease) in trade payables, current | 2,814.34 | |
| Adjustments for increase (decrease) in trade payables, non-current | 0.00 | |
| Adjustments for increase (decrease) in other current liabilities | 0.00 | |
| Adjustments for increase (decrease) in other non-current liabilities | 423.54 | |
| Adjustments for depreciation and amortisation expense | 660.29 | |
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 0.00 | |
| Adjustments for provisions, current | (40.45) | |
| Adjustments for provisions, non-current | 0.00 | |
| Adjustments for other financial liabilities, current | 262.18 | |
| Adjustments for other financial liabilities, non-current | 0.00 | |
| Adjustments for unrealised foreign exchange losses gains | 0.00 | |
| Adjustments for dividend income | 175.27 | |
| Adjustments for interest income | 1,677.31 | |
| Adjustments for share-based payments | 0.00 | |
| Adjustments for fair value losses (gains) | (1,931.61) | |
| Adjustments for undistributed profits of associates | 0.00 | |
| Other adjustments for which cash effects are investing or financing cash flow | (2,983.96) | |
| Other adjustments to reconcile profit (loss) | 0.00 | |
| Other adjustments for non-cash items | 397.95 | |
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0.00 | |
| Total adjustments for reconcile profit (loss) | (6,713.69) | |
| Net cash flows from (used in) operations | (6,949.45) | |
| Dividends received | 0.00 | |
| Interest paid | 0.00 | |
| Interest received | 0.00 | |
| Income taxes paid (refund) | 433.53 | |
| Other inflows (outflows) of cash | 0.00 | |
| Net cash flows from (used in) operating activities | (7,382.98) | |
| Cash flows from used in investing activities | ||
| Cash flows from losing control of subsidiaries or other businesses | 1.00 | |
| Cash flows used in obtaining control of subsidiaries or other businesses | 0.00 | |
| Other cash receipts from sales of equity or debt instruments of other entities | 80,050.97 | |
| Other cash payments to acquire equity or debt instruments of other entities | 70,355.29 | |
| Other cash receipts from sales of interests in joint ventures | 0.00 | |
| Other cash payments to acquire interests in joint ventures | 0.00 | |
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0.00 | |
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0.00 | |
| Proceeds from sales of property, plant and equipment | 12.19 | |
| Purchase of property, plant and equipment | 1,493.15 | |
| Proceeds from sales of investment property | 0.00 | |
| Purchase of investment property | 0.00 | |
| Proceeds from sales of intangible assets | 0.00 | |
| Purchase of intangible assets | 0.00 | |
| Proceeds from sales of intangible assets under development | 0.00 | |
| Purchase of intangible assets under development | 0.00 | |
| Proceeds from sales of goodwill | 0.00 | |
| Purchase of goodwill | 0.00 | |
| Proceeds from biological assets other than bearer plants | 0.00 | |
| Purchase of biological assets other than bearer plants | 0.00 | |
| Proceeds from government grants | 0.00 | |
| Proceeds from sales of other long-term assets | 0.00 | |
| Purchase of other long-term assets | 0.00 | |
| Cash advances and loans made to other parties | 0.00 | |
| Cash receipts from repayment of advances and loans made to other parties | 0.00 | |
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0.00 | |
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0.00 | |
| Dividends received | 175.27 | |
| Interest received | 1,125.54 | |
| Income taxes paid (refund) | 0.00 | |
| Other inflows (outflows) of cash | 7,602.29 | |
| Net cash flows from (used in) investing activities | 17,118.82 | |
| Cash flows from used in financing activities | ||
| Proceeds from changes in ownership interests in subsidiaries | 0.00 | |
| Payments from changes in ownership interests in subsidiaries | 10,000.00 | |
| Proceeds from issuing shares | 0.00 | |
| Proceeds from issuing other equity instruments | 0.00 | |
| Payments to acquire or redeem entity's shares | 0.00 | |
| Payments of other equity instruments | 0.00 | |
| Proceeds from exercise of stock options | 0.00 | |
| Proceeds from issuing debentures notes bonds etc | 0.00 | |
| Proceeds from borrowings | 2,209.32 | |
| Repayments of borrowings | 0.00 | |
| Payments of lease liabilities | 105.68 | |
| Dividends paid | 0.00 | |
| Interest paid | 62.56 | |
| Income taxes paid (refund) | 0.00 | |
| Other inflows (outflows) of cash | 0.00 | |
| Net cash flows from (used in) financing activities | (7,958.92) | |
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 1,776.92 | |
| Effect of exchange rate changes on cash and cash equivalents | ||
| Effect of exchange rate changes on cash and cash equivalents | 0.00 | |
| Net increase (decrease) in cash and cash equivalents | 1,776.92 | |
| Cash and cash equivalents cash flow statement at beginning of period | 1,242.15 | |
| Cash and cash equivalents cash flow statement at end of period | 3,019.07 | |
| Particulars | Year ended (dd-mm-yyyy) | ||
|---|---|---|---|
| Date of start of reporting period | 01-04-2025 | ||
| Date of end of reporting period | 31-03-2026 | ||
| Whether results are audited or unaudited | Audited | ||
| Nature of report standalone or consolidated | Consolidated | ||
| Assets | |||
| 1 | Finanical Asset | ||
| Cash and cash equivalents | 3,019.07 | ||
| Bank Balance other than (a) above | 2.57 | ||
| Derivative financial instruments | 0.00 | ||
| Receivables | |||
| (I) Trade Receivables | 765.58 | ||
| (II) Other Receivables | 0.00 | ||
| Loans | 945.70 | ||
| Investments | 51,868.15 | ||
| Other Financial assets | |||
| 1 | Other Financial Assets | 2,468.48 | |
| Total of Other Financial assets | 2,468.48 | ||
| Total Financial Assets | 59,069.55 | ||
| 2 | Non Financial Asset | ||
| Inventories | 14,464.50 | ||
| Current tax assets (Net) | 1,045.48 | ||
| Deferred tax Assets (Net) | 1,372.10 | ||
| Investment Property | 221.56 | ||
| Biological assets other than bearer plants | 0.00 | ||
| Property, Plant and Equipment | 7,817.22 | ||
| Capital work-in-progress | 119.84 | ||
| Intangible assets under development | 0.00 | ||
| Goodwill | 3,614.34 | ||
| Other Intangible assets | 10.12 | ||
| Other non-financial assets | |||
| 1 | Other Non- Financial Assets | 5,830.18 | |
| 2 | Assets held for sale | 11.98 | |
| Total of Other non-financial assets | 5,842.16 | ||
| Total Non Financial Assets | 34,507.32 | ||
| Total assets | 93,576.87 | ||
| Equity and liabilities | |||
| 1 | Equity | ||
| Equity attributable to owners of parent | |||
| Equity share capital | 3,181.05 | ||
| Other equity | 60,907.76 | ||
| Total equity attributable to owners of parent | 64,088.81 | ||
| Non controlling interest | 1243836000 | ||
| Total equity | 76,527.17 | ||
| 2 | Liabilities | ||
| 2.1 | Financial Liabilities | ||
| (a) | Derivative financial instruments | 0.00 | |
| (b) | Payables | 0.00 | |
| (I)Trade Payables | |||
| (i) total outstanding dues of micro enterprises and small enterprises | 2,735.95 | ||
| (ii) total outstanding dues of creditors other than micro enterprises and small enterprises | 5,866.13 | ||
| II) Other Payables | |||
| (i) total outstanding dues of micro enterprises and small enterprises | 0.00 | ||
| (ii) total outstanding dues of creditors other than micro enterprises and small enterprises | 0.00 | ||
| (C ) | Debt Securities | 0.00 | |
| (d) | Borrowings (Other than Debt Securities) | 2,209.32 | |
| (e) | Deposits | 0.00 | |
| (f) | Subordinated Liabilities | 0.00 | |
| Other financial liabilities | |||
| 1 | Other Financial Liabilities | 3,363.07 | |
| Total of Other financial liabilities | 3,363.07 | ||
| Total Financial Liabilities | 14,174.47 | ||
| 2.2 | Non-Financial Liabilities | ||
| (a) | Current tax liabilities (Net) | 522.13 | |
| (b) | Provisions | 856.59 | |
| (C ) | Deferred tax liabilities (Net) | 542.60 | |
| Other non-financial liabilities | |||
| 1 | Other Non- financial Liabilities | 953.91 | |
| Total of Other non-financial liabilities | 953.91 | ||
| Total Non Financial Liabilities | 2,875.23 | ||
| Total liabilities | 17,049.70 | ||
| Total equity and liabilites | 93,576.87 | ||
| Disclosure of notes on assets and liabilities | |||
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| Whether results are audited or unaudited | Audited | Audited | |
| Nature of report standalone or consolidated | Consolidated | Consolidated | |
| 1 | Segment Revenue (Income) | ||
| (net sale/income from each segment should be disclosed) | |||
| 1 | Financial Services | (436.22) | 1,333.64 |
| 2 | Healthcare Network | 35,537.34 | 1,28,316.06 |
| 3 | Others | 2,276.89 | 2,276.89 |
| Total Segment Revenue | 37,378.01 | 1,31,926.59 | |
| Less: Inter segment revenue | |||
| Revenue from operations | 37,378.01 | 1,31,926.59 | |
| 2 | Segment Result | ||
| Profit (+) / Loss (-) before tax and interest from each segment | |||
| 1 | Financial Services | (500.68) | 1,070.77 |
| 2 | Healthcare Network | (2,314.40) | (6,663.26) |
| 3 | Others | 95.50 | 95.50 |
| Total Profit before tax | (2,719.58) | (5,496.99) | |
| i. Finance cost | 48.82 | 78.17 | |
| ii. Other Unallocable Expenditure net off Unallocable income | (1,285.83) | (5,339.40) | |
| Profit before tax | (1,482.57) | (235.76) | |
| 3 | (Segment Asset - Segment Liabilities) | ||
| Segment Asset | |||
| 1 | Financial Services | 11,695.09 | 11,695.09 |
| 2 | Healthcare Network | 77,137.18 | 77,137.18 |
| 3 | Others | 0.00 | 0.00 |
| Total Segment Asset | 88,832.27 | 88,832.27 | |
| Un-allocable Assets | 4,744.60 | 4,744.60 | |
| Net Segment Asset | 93,576.87 | 93,576.87 | |
| 4 | Segment Liabilities | ||
| Segment Liabilities | |||
| 1 | Financial Services | 573.15 | 573.15 |
| 2 | Healthcare Network | 16,343.82 | 16,343.82 |
| 3 | Others | 0.00 | 0.00 |
| Total Segment Liabilities | 16,916.97 | 16,916.97 | |
| Un-allocable Liabilities | 132.73 | 132.73 | |
| Net Segment Liabilities | 17,049.70 | 17,049.70 | |
| Disclosure of notes on segments | |||
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Remeasurement gain/loss on defined benefit plans | 10007000 | 19009000 |
| Total Amount of items that will not be reclassified to profit and loss | 10007000 | 19009000 | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 23.89 | 42.54 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Fair value changes on equity instrument through OCI | 9470000 | 9470000 |
| Total Amount of items that will be reclassified to profit and loss | 9470000 | 9470000 | |
| 4 | Income tax relating to items that will be reclassified to profit or loss | 23.84 | 23.84 |
| 5 | Total Other comprehensive income | 147.04 | 218.41 |
| Whether results are audited or unaudited | Audited |
|---|---|
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | J K V S & CO | Yes | 30-11-2027 | ||
|---|---|---|---|---|---|